Secretary's Advisory Committee on Genetics, Health, and Society

Eighth Meeting October 19-20, 2005 North Bethesda, MD

$A \mathrel{G} E \mathrel{N} D \mathrel{A}$

Wednesday, October 19, 2005

8:30 a.m. – 8:35 a.m.	Opening Remarks
	Cynthia E. Berry, J.D.
	Acting SACGHS Chair

Large Population Studies Session

8:35 a.m. – 9:00 a.m. Session Overview and Report from the SACGHS Task Force on Large Population Studies Huntington F. Willard, Ph.D. SACGHS Task Force Chair

Policy Perspectives from Members of the Scientific Community

9:00 a.m. – 9:20 a.m.	Gerald R. Fink, Ph.D. Professor of Genetics Whitehead Institute for Biomedical Research Massachusetts Institute of Technology
9:20 a.m. – 9:30 a.m.	Q&A
9:30 a.m. – 9:50 a.m.	Sharon Kardia, Ph.D. Associate Professor of Epidemiology Director, Public Health Genetic Program University of Michigan School of Public Health
9:50 a.m. – 10:00 a.m.	Q&A
10:00 a.m. – 10:20 a.m.	Richard B. Marchase, Ph.D. Vice President for Science Policy Federation of American Societies for Experimental Biology

10:20 a.m. – 10:30 a.m.	Q&A
10:30 a.m. – 11:15 a.m.	Roundtable Discussion with Presenters Facilitator: Dr. Willard
11:15 a.m. – 11:30 a.m.	Public Comments
11:30 a.m. – 12:00 p.m.	Remarks of the Acting SACGHS Chair (continued) Ms. Berry
12:00 p.m. – 1:00 p.m.	LUNCH
Exploring Mechanisms for Publ	ic Engagement
1:00 p.m. – 1:20 p.m.	Joan A. Scott, M.S., CGC Deputy Director Genetics & Public Policy Center
1:20 p.m. – 1:40 p.m.	Toby Citrin, J.D. Adjunct Professor of Health Management and Policy Director, Michigan Center for Genomics and Public Health University of Michigan School of Public Health
	E. Yvonne Lewis Executive Director Faith Access to Community Economic Development
1:40 p.m. – 2:00 p.m.	Mary Woolley, M.A. President Research!America
2:00 p.m. – 3:00 p.m.	Roundtable Discussion with Presenters Facilitator: Kevin FitzGerald, S.J., Ph.D., Ph.D.
3:00 p.m. – 3:15 p.m.	BREAK
Policy Perspectives from Memb	ers of the Bioethics Community
3:15 p.m. – 3:35 p.m.	Henry T. Greely, J.D. Deane F. and Kate Edelman Johnson Professor of Law Stanford Law School
3:35 p.m. – 3:55 p.m.	Pilar Ossorio, Ph.D., J.D. Assistant Professor of Law and Medical Ethics Associate Director, Center for the Study of Race and Ethnicity in Medicine University of Wisconsin Law School

3:55 p.m. – 4:15 p.m.	Troy Duster, Ph.D.
	Professor of Sociology Director, Institute for the History of the Production of Knowledge New York University
4:15 p.m. – 5:00 p.m.	Roundtable Discussion with Presenters Facilitator: Ellen Fox, M.D.
5:00 p.m. – 6:00 p.m.	Discussion of Next Steps, Work Plan and Final Work Product for Large Population Studies Facilitators: Dr. Willard and Ms. Berry

Thursday, October 20, 2005

Genetic Discrimination Session

8:30 a.m. – 8:45 a.m.	Update on the Status of the Genetic Information Nondiscrimination Act of 2005 (S. 306/H.R. 1227) Sharon F. Terry, M.A. Coalition for Genetic Fairness
8:45 a.m. – 9:15 a.m.	Public Attitudes toward Advances in Genetics, Genetic Privacy and the Potential Misuse of Genetic Information Ms. Christy White Cogent Research
9:15 a.m. – 9:30 a.m.	Q&A and Committee Discussion
Pharmacogenomics Session	
9:30 a.m. – 9:45 a.m.	Update from the SACGHS Task Force on Pharmacogenomics Emily S. Winn-Deen, Ph.D. SACGHS Task Force Chair
9:45 a.m. – 10:05 a.m.	Update from FDA Steven I. Gutman, M.D., M.B.A. Director, Office of In Vitro Diagnostics U.S. Food and Drug Administration
	Allen Rudman, Ph.D. Associate Director, Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation and Research, FDA
10:05 a.m. – 10:30 a.m.	Q&A and Committee Discussion Facilitator: Dr. Winn-Deen
10:30 a.m. – 10:45 a.m.	BREAK
10:45 a.m. – 11:00 a.m.	Public Comments

11:00 a.m. – 11:25 a.m.	Feasibility of Integrating Pharmacogenomics into Drug Development from an Economic Perspective Thomas A. Metcalfe Head of Biomarker Program F. Hoffmann-La Roche Ltd
11:25 a.m. – 11:50 a.m.	Economic Challenges of Integrating Pharmacogenomics into Clinical Practice Kathryn Phillips, Ph.D. Professor of Health Economics and Health Services Research Director, Program in Pharmacogenomics and Population Screening University of California, San Francisco
11:50 a.m. – 12:15 p.m.	Q&A and Committee Discussion Facilitator: Dr. Winn-Deen
12:15 p.m. – 1:15 p.m.	LUNCH
1:15 p.m. – 1:45 p.m.	Ethical and Social Issues Associated with Using Race and Genetics in the Study of Differential Drug Response Wylie Burke, M.D., Ph.D. Professor and Chair, Department of Medical History and Ethics University of Washington
1:45 p.m. – 2:15 p.m.	Q&A and Committee Discussion Facilitator: Dr. Winn-Deen
2:15 p.m. – 3:15 p.m.	Discussion of Next Steps, Work Plan, and Final Work Product for Pharmacogenomics Facilitators: Dr. Winn-Deen and Ms. Berry
3:15 p.m. – 3:30 p.m.	Planning for March 2006 SACGHS Meeting and Concluding Remarks Ms. Berry
	ADJOURN